Vinpocetine
- Atc Codes:N06BX18
- CAS Codes:42971-09-5
- PHARMGKB ID:42971-09-5
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
Brand Names
Europe
Bulgaria: Cavinton, Vicerin, Vinpocetine; Czech Republic: Cavinton, Vicebrol, Vinpocetine; Hungary: Cavinton, Vinpocetin; Lithuania: Cavinton, Vinpocetine; Poland: Cavinton, Recervin, Vicebrol, Vinpocetine, Vinpoton; Portugal: Cavinton, Ultravinca, Vinpocetina, Vipocem; Romania: Cavinton, Vicebrol, Vinpocetin; Slovakia: Cavinton, Vinpocetine; Spain: Vinpocetina.
Drug combinations
Chemistry
Vinpocetine: C~22~H~26~N~2~O~2~. Mw: 350.45. (1) Ebunarmenine-14-carboxylic acid, ethyl ester, (3α, 16α); (2) Ethyl apovincamin-22-oate. CAS-42971-09-5 (1981).
Pharmacologic Category
Anti-Dementia Agents; Vasoactive agents. Vincamine Derivative. Nutritional Supplements. (ATC-Code: N06BX18).
Mechanism of action
Possesses various mechanisms of action: effects on brain circulation and oxygen utilization without changes in systemic circulation, increased tolerance of brain to vascular hypoxia and ischemia, anticonvulsant activity, phosphodiesterase-1 inhibition, and lowering of blood viscosity and inhibition of aggregation of thrombocytes.
Therapeutic use
Treatment of cognitive disorders associated with cerebral vascular pathology.
Pregnancy and lactiation implications
Use should be avoided during pregnancy and lactation.
Unlabeled use
Contraindications
Should not be used in severe, general, cerebral hypertensive crises, or in elderly or senile patients with acute cardio-cerebral or cerebro-cardiac syndrome, postinfarction cardiosclerosis, or marked disorders of heart rhythm.